Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Change in Accured Expenses: 2020-2025

Historic Change in Accured Expenses for GeneDx Holdings (WGS) over the last 5 years, with Sep 2025 value amounting to -$2.0 million.

  • GeneDx Holdings' Change in Accured Expenses fell 165.73% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.5 million, marking a year-over-year increase of 49.69%. This contributed to the annual value of -$20.5 million for FY2024, which is 56.42% up from last year.
  • Latest data reveals that GeneDx Holdings reported Change in Accured Expenses of -$2.0 million as of Q3 2025, which was up 44.44% from -$3.6 million recorded in Q2 2025.
  • Over the past 5 years, GeneDx Holdings' Change in Accured Expenses peaked at $42.3 million during Q2 2022, and registered a low of -$14.5 million during Q3 2023.
  • For the 3-year period, GeneDx Holdings' Change in Accured Expenses averaged around -$5.7 million, with its median value being -$6.1 million (2024).
  • Within the past 5 years, the most significant YoY rise in GeneDx Holdings' Change in Accured Expenses was 21,511.41% (2021), while the steepest drop was 26,465.84% (2021).
  • Over the past 5 years, GeneDx Holdings' Change in Accured Expenses (Quarterly) stood at $21.0 million in 2021, then tumbled by 71.88% to $5.9 million in 2022, then crashed by 219.28% to -$7.0 million in 2023, then tumbled by 79.74% to -$12.7 million in 2024, then slumped by 165.73% to -$2.0 million in 2025.
  • Its Change in Accured Expenses stands at -$2.0 million for Q3 2025, versus -$3.6 million for Q2 2025 and $10.8 million for Q1 2025.